BioCryst Initiates Phase II Clinical Trial to Evaluate Intravenous Peramivir in Patients Hospitalized With Influenza

BioCryst Initiates Phase II Clinical Trial to Evaluate Intravenous Peramivir in Patients Hospitalized With Influenza: "BIRMINGHAM, Ala., July 24 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. today announced the initiation of a Phase II clinical trial in hospitalized patients using an intravenous (i.v.) formulation of peramivir, the company's lead influenza neuraminidase inhibitor. The trial will compare the efficacy and safety of intravenous peramivir to orally administered oseltamivir in patients who require hospitalization due to acute influenza."